Last $7.88 USD
Change Today +0.05 / 0.64%
Volume 495.2K
As of 11:17 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Open
$7.84
Previous Close
$7.83
Day High
$7.95
Day Low
$7.62
52 Week High
01/8/15 - $9.63
52 Week Low
04/16/14 - $1.77
Market Cap
750.8M
Average Volume 10 Days
1.3M
EPS TTM
$-0.89
Shares Outstanding
95.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMICUS THERAPEUTICS INC (FOLD)

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

92 Employees
Last Reported Date: 03/3/14
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $824.1K
President and Chief Operating Officer
Total Annual Compensation: $475.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $445.1K
Compensation as of Fiscal Year 2013.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics, Inc. Appoints Bradley L. Campbell as President and Chief Operating Officer

On January 12, 2015, the board of directors of Amicus Therapeutics, Inc. announced the appointment of Bradley L. Campbell as president and chief operating officer, effective immediately. Prior to this appointment, Campbell served as chief operating officer since December 2013 and chief business officer since February 2012.

Amicus Therapeutics, Inc. Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study

Amicus Therapeutics announced additional positive data on an important cardiac endpoint from its first Phase 3 study and the Phase 3 extension of the oral small molecule chaperone migalastat HCl for Fabry disease. Data from the Fabry Registry indicate that the cause of death in patients is from cardiovascular disease1. In Study 011 and Study 041, previously untreated patients with amenable mutations showed a statistically significant decrease in left ventricular mass index (LVMi) following treatment with migalastat for up to 36 months (average of 22 months).

Amicus Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:30 AM

Amicus Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 10:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: John F. Crowley, Chairman and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $7.88 USD +0.05

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies
 

Industry Analysis

FOLD

Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 414.8x
Price/Book 14.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 438.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit www.amicustherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.